-
One-step TUNEL Cy3 Apoptosis Detection Kit Guide
2026-09-14
Learn how to apply a Cy3-based TUNEL workflow to cultured cells, frozen tissue, and paraffin sections while separating apoptotic DNA fragmentation from broader cell-death signals. The guide connects assay design with a glioblastoma study of mitochondrial stress, providing practical controls, optimization parameters, and troubleshooting strategies.
-
NU7441 (KU-57788): DNA-PK Assay Strategy
2026-09-13
NU7441 (KU-57788) is a selective DNA-PK probe for connecting kinase inhibition with DNA repair, cell-cycle, and apoptosis readouts. This guide develops an evidence-led assay strategy informed by oncology research and a 2018 study of DNA damage responses in latent HIV-1 infection.
-
Lidocaine With Epinephrine Shortage: Evidence and Solutions
2026-09-12
Bodie, Brodell, and Helms analyze the United States shortage of lidocaine with epinephrine, identifying manufacturer withdrawals and an epinephrine supply bottleneck as the principal causes. Their practice-focused recommendations address dose conservation, multidose-vial stewardship, dilution strategies, syringe stability, and clinically important limitations of substituting plain lidocaine.
-
BI 2536: From Mitotic Arrest to Translational Signal
2026-09-11
BI 2536 is more than a potent PLK1 inhibitor: it is a mechanistic probe for separating reversible cell-cycle arrest from irreversible apoptosis. This thought-leadership guide outlines how to translate its selectivity, assay behavior, and tumor xenograft evidence into stronger cancer research decisions.
-
Brefeldin A: Mapping ER Stress by Trafficking
2026-09-11
Brefeldin A is more than a vesicle transport inhibitor: it is a temporal probe for connecting ER-to-Golgi disruption with protein quality control and apoptosis. This article integrates BFA assay design with UBR1/UBR2 biology to improve mechanistic interpretation in cancer and cell biology research.
-
GPER1 as a Chemoprevention Target in Prostate Cancer
2026-09-10
The reference study identifies G-protein coupled estrogen receptor 1 (GPER1) as a potentially protective regulator during the transition from high-grade prostatic intraepithelial neoplasia to prostate cancer. By combining human samples, public datasets, TRAMP mice, pharmacological perturbation, and cell-based assays, it provides preclinical evidence that GPER1 activation may suppress tumor progression and epithelial-to-mesenchymal transition.
-
Tropisetron Hydrochloride: Assay Workflows
2026-09-10
Build reproducible receptor, transporter, and polarized-cell assays with Tropisetron Hydrochloride while separating 5-HT3 signaling from OCT2/MATE1 effects. This workflow translates comparative antiemetic transporter data into practical concentration selection, controls, and troubleshooting decisions.
-
Vitamin K2, NRF2/FSP1, and Osteoblast Ferroptosis
2026-09-09
Zhang et al. report that vitamin K2 partially preserves bone mass in a dexamethasone-induced osteoporosis model by restoring NRF2/FSP1-associated antioxidant defenses, mitochondrial function, and osteoblast differentiation. The study positions osteoblast ferroptosis and lipid peroxidation as mechanistically relevant features of glucocorticoid-induced osteoporosis, while also providing a framework for testing redox-focused interventions.
-
Deferasirox Pharmacokinetics and Clinical Evidence
2026-09-09
Galanello, Campus, and Origa provide a clinically oriented synthesis of deferasirox pharmacokinetics, pharmacodynamics, efficacy, and safety across transfusion-dependent anemias. The review’s main contribution is linking oral chelation exposure and disease-specific iron burden to practical dosing, monitoring, and interpretation of treatment response.
-
Isoproterenol Sulfate Dihydrate: Assay Logic
2026-09-08
Isoproterenol sulfate dihydrate can do more than accelerate beating in human SAN assembloids. This guide explains how to use beta-adrenergic stimulation as a causal assay layer for separating receptor responsiveness, pacemaker maturation, and neuro-cardiac organization.
-
Birinapant and the Next Frontier in Apoptosis
2026-09-08
MDM1–p53 biology offers a compelling framework for studying chemoradiotherapy sensitivity, while Birinapant (TL32711) provides a pharmacological route to probe IAP-controlled apoptosis. This article connects the two areas, defines a practical validation workflow, and distinguishes mechanistic opportunity from translational evidence.
-
Chlamydial Vesicles Deliver OmpA to Mitochondria
2026-09-07
Mesesan and colleagues show that Chlamydia trachomatis uses chlamydia-derived vesicles to transport the β-barrel protein OmpA to host mitochondria, where it engages BAK and promotes BAX retro-translocation to suppress apoptosis. The study connects vesicle trafficking, mitochondrial membrane biology, and pathogen persistence while providing a mechanistic framework for interpreting BAX/BAK-dependent apoptosis assays.
-
MDockPeP2_VS for Peptide Inhibitor Discovery
2026-09-07
The 2024 PNAS Nexus study introduces MDockPeP2_VS, an automated structure-based workflow that uses molecular docking and structural conservation to make large-scale peptide screening more practical. Applied to Escherichia coli TEM-1 β-lactamase, the method identified peptide TF7, which inhibited enzymatic activity with a reported Ki of 1.37 ± 0.37 μM, providing a computational starting point for antibiotic-resistance research.
-
Azilsartan Medoxomil: Evidence From a 2024 Meta-Analysis
2026-09-05
This systematic review and meta-analysis integrated efficacy and safety evidence from 11 randomized controlled trials of azilsartan medoxomil in hypertension. The findings support dose-related blood pressure reduction without a broad increase in adverse events, while the small diabetes subgroup and limited clinical scope require cautious interpretation.
-
PPM-18: Reliable iNOS Assay Design
2026-09-04
This scenario-driven guide explains how SKU C4074, PPM-18 (N-(1,4-dihydro-1,4-dioxo-2-naphthalenyl)-benzamide), can improve interpretation of viability, proliferation, and inflammatory-response assays. It connects mechanism, solvent compatibility, dose selection, orthogonal readouts, and vendor-quality checks for reproducible inflammation and sepsis research.